drugset
drugset / Trial / NCT00669877

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

NCT00669877 ↗

Phase 2 Completed 56 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma. Another goal is to see how well this treatment works when given with Rituximab. The safety of the combined treatment will also be studied.

Timeline

Start
2002-08
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject Cytarabine Small molecule 100 mg Intrathecal
Subject Cytarabine Small molecule 3 g Intrathecal
Subject Dexamethasone Small molecule 40 mg Intravenous
Subject Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Subject Methotrexate Small molecule 200 mg/m2 Intravenous
Subject Methotrexate Small molecule 800 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Vincristine Small molecule 2 mg Intravenous
Background G-CSF Unknown 10 ug/kg Intravenous
Background Pegfilgrastim Protein / enzyme biologic — Subcutaneous

Indications

Burkitt lymphoma